Skip to main content
. Author manuscript; available in PMC: 2023 Feb 2.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1621–1629. doi: 10.1158/1055-9965.EPI-21-1296

Figure 3.

Figure 3.

Clinical category assignment for individuals with a TP53 pathogenic variants. The figure depicts the overall proportion of the clinical categories (germline, ACE/CHIP, PZM) found in this clinic based genetic testing cohort. Based on cascade/transmission testing, clinical criteria, and/or multi tissue analyses, 89/134 (66%) cases had evidence for germline, 26/134 (19%) were categorized as ACE, and 7/134 (5.2%) had evidence for PZM. Additional tissue or transmission data would be needed to discern PZM from broader ACE category for the 12/134 (9%) that were indeterminate.